IMAGE CREDITS: COREWIRE / AI ILLUSTRATION

Oxylabs takes first outside capital: $130M at $3.6B

Oxylabs, the bootstrapped Vilnius web-data firm, took its first outside capital: a $130 million growth investment from Warburg Pincus at a $3.6 billion valuation. The check validates web data supply as AI-grade infrastructure for agents.

Oxylabs, the Vilnius-based web data collection and scraping infrastructure company, has taken its first outside investment in roughly a decade: a $130 million growth check from Warburg Pincus that values the company at $3.6 billion. The deal, announced on July 9, came through the Warburg Pincus Capital Solutions Founders Fund.

The number that matters here is not the valuation, it is the source. A top-tier private equity firm managing over $105 billion in assets just priced web data supply, the raw material behind AI training and agentic applications, as unicorn-grade infrastructure. That reframes large-scale scraping from a gray-area utility into a category worth a nine-figure institutional bet.

What’s actually new

Founded in 2015, Oxylabs bootstrapped for roughly a decade before this raise. In its own announcement, the company reports a reported $350 million in annual recurring revenue, more than 350,000 tech-team customers (including Fortune 500 and AI companies), and a portfolio of 160-plus patents, while handling billions of web requests daily. Reaching that scale without a single prior outside round is the rare part.

The capital is earmarked for three things: next-generation product development, expanding the global proxy network, and advancing the company’s AI and agentic data infrastructure. CEO Vytautas Savickas framed the thesis around AI agents that now navigate the web far more than humans ever have, arguing the future belongs to data infrastructure that grounds these systems in real time. Warburg Pincus principal Allison Ross called Oxylabs a leader in web intelligence. CFO Jurgis Gabrielius Rudgalvis pointed to prior acquisitions of Webshare Software in 2022 and ScrapingBee in 2025 as portfolio-broadening moves that set up this round.

Oxylabs is the second unicorn to emerge from the Tesonet accelerator and now ranks among Lithuania’s highest-valued private companies. The pattern echoes other 2026 raises where institutional money validated a category: SambaNova’s $1 billion round with JPMorgan as proof did the same for inference hardware.

What this means for teams that buy web data

For engineering and data teams, the read is straightforward. Your web data vendor just got a strategic, patient balance sheet and a mandate to expand its proxy network and agentic tooling. That should mean broader coverage and more first-party investment in the reliability layer, at the cost of further consolidation: Oxylabs is buying, not being bought, and each acquisition narrows the independent-vendor field.

The deeper shift is why the check exists at all. Agents that browse, retrieve, and act need a supply of clean, real-time web data, and that demand is compounding as agentic usage overtakes chatbot search. It is the same velocity story now visible across the sector, where AI-adjacent firms hit nine-figure revenue in months, not years. Buyers evaluating a data pipeline for an agent stack should now treat proxy and scraping infrastructure as a core dependency with real lock-in, not a commodity line item.

What to watch

Posts circulating on X, including the official @Lithuania account, are calling this the country’s sixth unicorn. That framing is unconfirmed: neither primary source states it, so treat the sixth-unicorn count as attribution to those posts, not fact. Also unstated in the releases is whether the $3.6 billion figure is strictly post-money. Watch how fast the promised agentic data tooling ships, and whether Warburg’s move triggers competing bids or matching raises among rival data vendors.

Get the Signal

AI and business tech news, verified by a physician who reads the filings. One email a week, no noise.

Dr. Joseph Joshua

Dr. Joseph Joshua is the founder and editor of Corewire. A medical doctor by training, he brings the evidence-first discipline of clinical medicine to technology journalism: claims get checked against primary sources before they get published. He has produced technology and B2B content for companies across…

View Bio

Keep Reading